Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2022Frontiers in ImmunologyOpen Access

C1q as a target molecule to treat human disease: What do mouse studies teach us?

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKristina SchulzUniversität HamburgMTMarten TrendelenburgUniversity of Basel

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Schulz et al. (2022) studied this question.

synapsesocial.com/papers/6a7949f68d250a4360f376e2https://doi.org/10.3389/fimmu.2022.958273
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Opsonization of Apoptotic Cells: Implications for Uptake and Autoimmunity2000 · 91 citations
  2. 2Increased Positive Selection of B1 Cells and Reduced B Cell Tolerance to Intracellular Antigens in c1q-Deficient Mice2007 · 36 citations
  3. 3C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy2017 · 13 citations
  4. 4Local externalization of phosphatidylserine mediates developmental synaptic pruning by microglia2020 · 450 citations
  5. 5C1q Deficiency and Autoimmunity: The Effects of Genetic Background on Disease Expression2002 · 229 citations